Consensus Launches First To Market Orthopedic Post-Surgical Wearable Device

Posted On March 9, 2017 By OrthoSpineNews In Recon /

SACRAMENTO, CA (PRWEB) MARCH 08, 2017

El Dorado Hills, CA, March 8th, 2017: Consensus Orthopedics, a joint reconstruction manufacturer, proudly announces its entry into the orthopedic wearable devices market. TracPatch is a groundbreaking wearable device that remotely monitors a patient’s post-surgical activities by continuously sending activity data, including range of motion (ROM), ambulation, exercise compliance, and wound site temperature trends. Healthcare Providers will now have insight 24/7 into how a patient is recovering from total joint surgery, thus improving outcomes and reducing costs. The TracPatch wearable device system will be debuted at next week’s American Academy of Orthopedic Surgeons Annual Meeting in San Diego, CA, March 14th-17th, 2017, Booth #1233.

The first six weeks of at-home recovery after total joint surgery are critical for a positive outcome. Visibility into the patient’s at-home activity is nonexistent. This limited insight along with the emergence of value-based medicine, including programs such as Comprehensive Care for Joint Replacement (CJR), signifies a new paradigm shift in cost control and responsibility for hospitals and surgeons. The Centers for Medicare & Medicaid Services, CMS, is sending a clear message with CJR: they want hospitals and post-acute providers to partner and coordinate for a patient’s entire 90-day episode of care. Through an IoT (Internet of Things) approach, TracPatch helps both the patient and healthcare provider coordinate care and accountability.

The TracPatch device is placed on the lower leg just below the joint line, using non-allergenic adhesive disposable pad. TracPatch is designed to enable any healthcare provider to collectively and continuously monitor their TracPatch patients’ progress. TracPatch will record patient’s range of motion (ROM), ambulation, exercise compliance, and temperature trends regardless of what implant system is used.

This machine learning device optimizes the patient’s entire episode of care by enabling a proactive approach. Whether the recovery is going well or needs immediate attention, the healthcare provider can adjust the patient’s post-surgical activities and goals anytime, anywhere to better facilitate and improve the patient’s recovery. The device transmits key post-surgical data points directly to a secure cloud-based platform, where healthcare providers can track patient progress on the TracPatch mobile app or web dashboard. The TracPatch app features an intuitive interface for easy operation on any smart phone or tablet with Bluetooth technology.

Dr. Shervin Oskouei, MD, Dept. of Orthopedic Surgery, Emory University School of Medicine, said “TracPatch can add tremendous value to the entire episode of care. This technology allows a healthcare provider insight into never-before-seen data for post-surgical rehabilitation. Being able to monitor your patient’s range of motion progress and exercise compliance daily is a game changer. TracPatch is making proactive care easy, so every patient has an excellent outcome.”

Curt Wiedenhoefer, President of Consensus Orthopedics, says, “In this new value-based healthcare environment, to be able to combine the exploding adoption of wearable technology and apply it to the total joint industry is going to revolutionize the way we deliver care. For the first time in the history of joint surgery, we are using microelectronics to passively capture valuable post-surgical recovery information. Now, healthcare providers have objective data for every patient, especially during those critical six weeks of post-acute care.”

With the launch of TracPatch, Consensus Orthopedics is ideally positioned to partner with all healthcare providers looking to improve outcomes, reduce costs and enhance patient satisfaction. With CJR bundled payments rolling out nationwide, TracPatch is a truly innovative product for the value-based healthcare market as well as any provider looking to redefine their episode of care.

Explore TracPatch by visiting Consensus Orthopedics Booth #1233 at the American Academy of Orthopedic Surgeons Annual Meeting in San Diego, March 15-17. See for yourself how this device can revolutionize the way you deliver care.

To learn more about the TracPatch wearable device system, visit tracpatch.com, call 916-355-7131, and visit Booth #1233 at AAOS.

About Consensus® Orthopedics, Inc.
Consensus Orthopedics was founded in 1992 as a medical device consulting company. In 1996, Consensus Orthopedics acquired US Medical Products, becoming a global manufacturer of reliable large joint orthopedic devices. In 2016, Consensus Orthopedics launched its innovative TracPatch division focused on creating transformative wearable technology designed for real time continuous post-surgical patient monitoring. With a focus on patient care, Consensus is dedicated to creating one team and providing exceptional outcomes. Learn more at http://www.consensusortho.com.

Hip Replacement Implant Market Forecast 2016 – 2024

Posted On March 7, 2017 By OrthoSpineNews In Recon /

NEW YORK, March 7, 2017 /PRNewswire/ — Hip Replacement Implant Market: Overview

Read the full report: http://www.reportlinker.com/p04760054-summary/view-report.html

Hip Replacement Implant are the artificial implant made of metal, plastics or ceramic which are replaced with the hip joint. Hip replacement procedure takes place when hip joint is damaged due to disease or injury.

A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the hip replacement implant market, has been provided in this report. Market revenue for all the above mentioned segments, and their sub segments has been provided for the forecast period of 2016-2024, considering 2015 as the base year, and 2014 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2016-2024. Market share estimations were based on in-depth analysis and study of products, and their features, prices etc.

This report provides in-depth analysis of the hip replacement implant market. The stakeholders for this report include companies involved in the manufacturing of hip implant and its spares parts. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the hip replacement implant market. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.

Global Hip Replacement Implant Market: Research Methodology

The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of Key Opinion Leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.

Global Hip Replacement Implant Market: Segmentation

Based on product type, global hip replacement implant market is segmented on the basis of product are total hip replacement implant, partial hip replacement implant, hip resurfacing implant and revision hip replacement implant. Total hip replacement implant segment is further sub-segmented into fixed bearing hip implants and mobile-bearing total hip implants. Based on material, the hip replacement implant market are segmented into metal-on-metal, metal-on-polyethylene, ceramic-on-metal, ceramic-on-polyethylene and ceramic-on-ceramic. End users in the hip replacement implant market are, hospitals, orthopedic clinics, ambulatory surgical centers and others (long term care center, research, academics, nursing facility, etc.)

Global Hip Replacement Implant Market: Regional Outlook

Based on geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, rest of Europe, China, Japan, Australia and New Zealand, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, Saudi Arabia, South Africa and Rest of Middle East and Africa.

Key Players Mentioned in this Report are:

The report also comprises list major players in the market, their SWOT analysis, market share of these players in the hip replacement implant market, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, B. Braun Melsungen AG, Exactech, Inc., DJO Global, Inc., Johnson & Johnson, MicroPort Scientific Corporation, OMNIlife science, Inc., Smith & Nephew, Stryker Corporation and Zimmer Biomet Holdings, Inc. Zimmer Biomet Holdings, Inc.

The global hip replacement implant market has been segmented as follows:

Global Hip replacement Implant Market, by Product Type
Total Hip Replacement Implant
Fixed Bearing Hip Implants
Mobile-Bearing Total Hip Implants
Partial Hip Replacement Implant
Hip resurfacing Implant
Revision Hip Replacement Implant

Global Hip Replacement Implant Market, by Material
Metal-on-metal
Metal-on-polyethylene
Ceramic-on-metal
Ceramic-on-polyethylene
Ceramic-on-ceramic

Global Hip Replacement Implant Market, by End Users
Hospitals
Orthopedic Clinics
Ambulatory Surgical Centers
Others

Global Hip Replacement Implant Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K.
Rest of Europe
Asia Pacific
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
Saudi Arabia
South Africa
Rest of MEA
Read the full report: http://www.reportlinker.com/p04760054-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

OrthAlign, Inc. Announces Full Commercial Launch of UniAlign™

Posted On March 7, 2017 By OrthoSpineNews In Recon /

ALISO VIEJO, CA (PRWEB) MARCH 06, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company providing orthopedic surgeons with precision tools, announced the full commercial launch of UniAlign™, the world’s first handheld navigation device for unicompartmental knee arthroplasty (UKA).

UniAlign provides surgeons with OrthAlign’s clinically-proven handheld navigation technology, along with instruments uniquely designed to address the demanding requirements for precision of UKA procedures. To date, OrthAlign technology has successfully been used in approximately 60,000 joint arthroplasty cases, worldwide.

“UniAlign has become an invaluable tool for my practice,” said Sridhar M. Durbhakula, MD of the Washington Joint Institute in Bethesda, MD. “It delivers a more efficient operation with precise bone cuts, no CT/MRI, minimal pin site morbidity, and it gives me real-time data so that I always know exactly what I’m doing. Patients will get home more quickly because UniAlign allows for a minimally invasive surgical approach that promotes faster patient recuperation. UniAlign is the ideal way to cost-effectively offer computer assisted surgery in the outpatient setting.”

UniAlign establishes the mechanical axis of the tibia, determining the varus/valgus angle and the posterior slope angle of the cutting block relative to the tibia, for the transverse resection. The system has been validated in simulated use testing to achieve resection accuracy of ±2.0° in the coronal plane, ±3.0° in the sagittal plane and ±2.0 mm in depth. This accuracy has been validated with at least 90% confidence.

“The introduction of UniAlign is just the beginning of OrthAlign’s new product rollout for 2017,” said Eric B. Timko, OrthAlign’s Chief Executive Officer and Chairman. “As OrthAlign’s biggest focus for this year is in expanding our customer reach and application pipeline, we will continue providing orthopedic surgeons and healthcare facilities with our clinically beneficial and economically friendly portfolio of products, staying true to our core design principles of ease of use, precision, and cost effectiveness.”

OrthAlign will be showcasing its full portfolio of products, including the recently launched UniAlign and Direct Anterior HipAlign® technologies at this year’s AAOS meeting in San Diego, CA, March 15-18, 2017 at booth #5615.

About OrthAlign, Inc.

OrthAlign is a privately held medical device and technology company, committed to providing orthopedic surgeons with cutting edge, user-friendly, surgical navigation products for precise alignment and positioning. We believe that our technology will raise the standard of care in Joint Arthroplasty surgeries by making consistent and measurable results accessible and affordable to all surgeons, hospitals, and patients. Our strategy is to leverage this technology to provide simple and precision-driven solutions for a broad range of orthopedic procedures. For more information regarding OrthAlign, please visit http://www.orthalign.com.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are registered trademarks of OrthAlign, Inc.”

Summit Orthopedics’ Vadnais Heights Surgery Center Receives The Joint Commission’s Advanced Certification

Posted On March 6, 2017 By OrthoSpineNews In Recon /

WOODBURY, Minn., March 6, 2017 /PRNewswire/ — Summit Orthopedics is to pleased to announce that its Vadnais Heights Surgery Center has earned The Joint Commission’s Gold Seal of Approval® for Advanced Certification for Total Hip and Total Knee Replacement. The facility is one of just two ambulatory surgery centers nationwide to receive the certification.

“We are incredibly honored that our Vadnais Heights Surgery Center has been recognized for its work in the area of advanced total hip and total knee replacements,” said Adam Berry, Summit CEO. “And I, personally, am very proud of our physicians and staff who work tirelessly to ensure the best possible outcomes for our patients who undergo these advanced treatments.”

The advanced certification was developed in response to the growing number of patients undergoing a total hip or total knee replacement surgery in the U.S. Also, there has been an increased focus on clinical evidence-based patient care as it relates to pain management, quality of life issues, functional limitation in mobility, and the return to normal daily activities.

According to the American Academy of Orthopaedic Surgeons, between 1993 and 2009, the number of total knee replacement surgeries more than tripled and the number of total hip replacements doubled. The increase in the number of surgeries is attributed in great part to the rise in obesity rates as well as an active baby boomer generation. Berry noted that since opening in 2014, Summit’s Vadnais Heights facility has performed more than 1,800 total hip and total knee replacements. With the opening of Summit’s Eagan Surgery Center in March, he anticipates that Summit will perform nearly 800 such surgeries between the two surgery centers in 2017.

“There’s certainly a high demand for these advanced surgeries, but we’re finding that there’s also a demand for exceptional care, accelerated recovery times, and reduced costs,” he said. “Patients want the best care available at the best price. Through our Vadnais Heights Surgery Center—and very shortly our new Eagan Surgery Center, Summit provides this service. And now The Joint Commission, the leading healthcare accreditation organization in the country, has recognized Summit’s value.”

Summit’s value, according to Berry, is reflected in key data points critical to patients, insurers and The Joint Commission. For example, since opening in 2014, the average satisfaction level for patients undergoing total hip or knee replacements at Summit’s Vadnais Heights facility was 96.2 out of 100; the average infection rate was between just .1 – .5 percent; and the average time between surgery and ambulation was between 3 hours and 10 minutes and three hours and 23 minutes, with patients traveling an average of 95 to 98 feet.

Summit Orthopedics’ Vadnais Heights facility is a one-stop, state-of-the-art center offering patients comprehensive orthopedic treatment that includes physician consultations, advanced imaging, therapy, bracing, orthotics, and a seven-day-a-week walk-in clinic. The facility also offers surgical care and overnight recovery in specialized care suites adjacent to the surgical facility for those undergoing advanced spine procedures and total joint replacements. In a concept still new to Minnesota and launched at Summit’s Vadnais Heights facility, the care suites, which will open in Eagan in March, offer personalized services, such as catered meals from local restaurants and one-on-one education and physical therapy, as well as hotel-level amenities, including Wi-Fi, lounge seating, and concierge services. In addition, the suites boast Secure Tracks, a post-surgery accelerated walking system exclusive to Summit Orthopedics that gets patients up and walking within hours of surgery.

Summit’s new Eagan facility, which opens this week, mirrors the Vadnais facility in treatment offerings and amenities. The Eagan Surgery Center will pursue this same certification from The Joint Commission.

About The Joint Commission
Founded in 1951, The Joint Commission seeks to continuously improve health care for the public, in collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission accredits and certifies more than 21,000 health care organizations and programs in the United States. An independent, nonprofit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

About Summit Orthopedics
Summit Orthopedics is privately owned and managed, with 50 highly trained orthopedic specialists teamed with 125 supporting providers such as physician assistants, therapists, and certified athletic trainers. For more than 30 years, Summit has provided a range of conservative and progressive care options for musculoskeletal conditions for patients across the Twin Cities, throughout Greater Minnesota and beyond. This includes prevention, surgical and non-surgical treatment, and rehabilitation. Summit employs about 850 people at 33 locations throughout Minnesota.

Contact:	Patty Gibbs
	Patty Gibbs & Company
	651.653.7302
	patty@pattygibbscompany.com

SOURCE Summit Orthopedics

U.S. Knee Implant Market to Register Substantial Expansion by 2024

Posted On March 3, 2017 By OrthoSpineNews In Recon /

03-02-2017 – Press release from: TMR, Research Reports

The U.S. market for knee implants a matured market and projected to witness steady growth over the forthcoming years. The technological advancements in knee implants, such as the usage of 3D printing, biocompatible materials, robotic-assisted surgeries, and navigation technology are likely to drive this market in coming years. Apart from this, the increasing health care expenditure and the rising population of geriatric individuals are also anticipated to contribute to the growth of this market significantly.

Browse Market Research Report @ www.transparencymarketresearch.com/us-knee-implant-market…

The U.S. knee implant market stood at US$4.3 bn in 2015 and is expected to protrude at a CAGR of 5.30% between 2016 and 2024 and reach US$7.0 bn by 2024.

Hospitals to Remain Key End Users of Knee Implants
Hospitals, ambulatory surgical centers, and specialized orthopedic clinics are the main end users of knee implants in the U.S. The demand for knee implants is much higher from hospitals than other end users. The hospitals segment held a share of more than 43% of the overall demand for knee implants in the country in 2015. With the presence of hospitals in a very large number, this segment is likely to remain the topmost end user of knee implants in the U.S.

Ambulatory surgery centers are also expected to emerge as a lucrative end-use segment for knee implant manufacturers in the U.S. over the next few years. As these centers offer modern health care facilities and emphasize on providing same-day surgical care, including diagnostics and preventive procedures, which has begun to reflect positively on the demand for knee implants from these centers. Apart from this, the shifting preference of patients from hospitals to ambulatory service centers, owing to the after care services, cost-effective care, and minimally invasive surgeries provided by the latter, is also projected to influence the demand for knee implants from these centers in the near future.

READ THE REST HERE

Michel Orsinger Joins Lima Corporate’s Advisory Board

Posted On March 2, 2017 By OrthoSpineNews In Recon /

SAN DANIELE DEL FRIULI, Italy, March 1, 2017 /PRNewswire/ —

Lima Corporate further strengthens the Advisory Board. Following the announcement regarding Mr. Bruno Melzi, Lima Corporate is proud to announce the arrival of another new Board Member: Michel Orsinger, former Chairman of Global Orthopedics Johnson & Johnson (J&J), has decided to join the Lima Advisory Board starting 1^st of March, 2017.

Michel Orsinger held the position of Worldwide Chairman DePuy Synthes Companies at J&J from 2012 to 2015. He was also a member of J&J’s Global Management Team. Michel Orsinger joined J&J following the sale of Synthes Inc. for $20 billion, the largest acquisition ever realized by Johnson & Johnson. Subsequently, Michel Orsinger established the worldwide’s largest and most comprehensive orthopedic company. Prior to his leadership role at Johnson & Johnson, Mr. Orsinger was COO and CEO of Synthes Inc for eight years, and spent eleven years with Novartis.

Today, Michel Orsinger is an investor as well as board member of several start-up companies and an advisor to EQT.

“The addition of Michel has further strengthened what was already one of the strongest Advisory Boards in the industry and is another proof of Lima’s attractiveness,” said Valentin Chapero, Chairman of the Advisory Board. “I am convinced that Michel’s outstanding industry knowledge and leadership experience will allow the Advisory Board to contribute additional value to Lima and its management team, specifically in further supporting growth,” Mr. Chapero concluded.

“I am very happy that Michel as another high quality veteran of our industry has decided to join the Advisory Board,” said Luigi Ferrari, CEO of Lima Corporate. “Michel’s expertise in the orthopaedic as well as medical device industry and track record of growing companies will accelerate our development,” Mr. Ferrari commented.

About Lima Corporate

Lima Corporate is a global medical device company providing reconstructive orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, Lima Corporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. Lima Corporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

For additional information on the Company, please visit http://www.limacorporate.com .

http://limacorporate.com/repo/transfers/8/Lima_Corporate_Press_Release_New_Board_Member_Orsinger.pdf

SOURCE Lima Corporate

OrthAlign, Inc. Appoints Eric B. Timko As New Chief Executive Officer and Chairman of the Board

Posted On March 2, 2017 By OrthoSpineNews In Recon /

ALISO VIEJO, CA (PRWEB) MARCH 01, 2017

OrthAlign, Inc., a privately held U.S.-based medical device and technology company, announced today the appointment of Eric B. Timko as its new Chief Executive Officer and Chairman of the Board.

Mr. Timko is an accomplished medical device executive with more than 25 years of experience in the healthcare industry. He assumes his new leadership role at OrthAlign after serving on the company’s Board of Directors since July 2016. He previously served as President and Chief Executive Officer of Blue Belt Technologies, which under his leadership, was sold to Smith & Nephew in October 2015.

“I am very appreciative and excited to join OrthAlign as Chairman and CEO,” said Mr. Timko. “With close to 60,000 cases of consistent clinical outcomes completed, OrthAlign’s technology has made a positive impact on improving patient outcomes in joint replacement and will continue to do so for many years to come. Our immediate focus will be to expand our customer reach and our application pipeline so that more physicians and healthcare facilities can utilize our clinically beneficial and economically friendly portfolio of products.”

Prior to joining Blue Belt Technologies, Mr. Timko served as President and Chief Executive Officer of NeuroVasx, Inc., President of Carl Zeiss Surgical, Inc., and as Vice President of Siemens Medical Systems, Inc.

“As OrthAlign hits another inflection point in its successful history, the Board of Directors is delighted to have Eric take the reigns as Chairman and CEO of the company,” said Carter McNabb, OrthAlign Board Member and Managing Director of River Cities Capital Funds. “Eric’s prior leadership experience throughout his career is tailor made for the next stage of growth that lies ahead for OrthAlign. He is one of the medical technology industry’s most respected and innovative executives and we are confident that his leadership and vision will help fulfill the promise that our unique technology can bring to the changing orthopedic landscape.”

“The Board of Directors would also like to recognize outgoing OrthAlign CEO William Maya for his leadership over the past six years,” continues Mr. McNabb. “He has been instrumental in helping guide the organization through a critical growth period and effectively helped put OrthAlign technology on the global map. The OrthAlign family is extremely grateful for his service.”

About OrthAlign, Inc.

“ORTHALIGN®, ORTHALIGN PLUS®, KNEEALIGN®, KNEEALIGN® 2, HIPALIGN®, and UNIALIGN™ are [registered] trademarks of OrthAlign, Inc.”

DJO Global Announces Appointment of Bryan McMillan as President, Regeneration

Posted On March 1, 2017 By OrthoSpineNews In Recon, Top Stories /

March 1, 2017

SAN DIEGO–(BUSINESS WIRE)–

DJO Global, Inc., a leading global provider of medical technologies designed to get and keep people moving, today announced the appointment of Bryan McMillan as President Regeneration, effective March 1, 2017.

As President of DJO’s Regeneration business, Mr. McMillan will be responsible for both commercial growth strategies and corporate payor development and reimbursement initiatives. Mr. McMillan will report directly to DJO President and Chief Executive Officer, Brady Shirley.

“We are very excited to announce the appointment of Bryan McMillan as President of our Regeneration Business, Reimbursement, and Payor Development to provide effective, affordable solutions, giving patients and providers the attention they deserve to enhance the continuum of care,” said Brady Shirley, DJO President and Chief Executive Officer. “Throughout his career, Bryan has proven to be an agile leader with an extensive understanding of our specific segment and healthcare economics. We are confident that his ability to thrive in a variety of business environments to reach collective goals will serve DJO Global well in its commitment of being a world class organization.”

Mr. McMillan most recently served as the President of CoorsTek Medical, a position he was appointed to in March of 2014 after completing the successful integration of IMDS (Innovative Medical Device Systems) to the Coors family enterprise. In his role, Mr. McMillan was responsible for all functional areas and strategy for a division of the largest engineered ceramics company worldwide.

From 2010 to 2012, Mr. McMillan served in several key leadership positions at Orthofix International, N.V., culminating in his final role there as President for the Global Spine Business Unit. Prior to Orthofix, Mr. McMillan had a successful nine-year tenure at Stryker Corporation, where he held significant roles of increased responsibility, ultimately being promoted to the position of Vice President, Stryker Finance. In this capacity, Mr. McMillan built, developed and led a cross-divisional entity for Stryker to offer internal financing and strategic sales programs. During the “Great economic recession” and with capital equipment sales down, he led the division to record sales with nearly 30% growth in 2009. A large part of his unprecedented achievements can be attributed to Mr. McMillan’s demonstrated leadership skills, unique business acumen, and ability to transform multi-discipline business strategies into tangible outcomes.

Prior to entering the medical device industry, Mr. McMillan spent nearly ten years in investment management and banking with prestigious firms such as Rauscher Pierce, Everen Securities and CIBC Oppenheimer. Mr. McMillan received a Bachelor’s degree in Political Science and Business with honors from Arizona State University, and successfully completed the Harvard Executive Leadership program and Strategic Marketing Curriculum at the University of Texas, Austin.

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, REGEN™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and Exos™. For additional information on the Company, please visit www.DJOglobal.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170301006385/en/

MicroPort Orthopedics Announces Results of Clinical Study, 98.8% Implant Survivorship of its Medial-Pivot Knee System at 17 Years

Posted On February 28, 2017 By OrthoSpineNews In Recon /

February 28, 2017

ARLINGTON, Tenn.–(BUSINESS WIRE)–MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced that The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.¹

It has been reported that approximately 20% of patients are not satisfied with the outcome of their total knee replacement as a result of residual pain and functional issues often attributed to implant design.² MicroPort’s Medial-Pivot Knee System is uniquely designed to restore stability and normal knee kinematics to deliver reproducible outcomes that can improve function and drive patient satisfaction.

“I am in my third year of using the Evolution® Medial-Pivot Knee System and this publication validates the results that I have seen in my practice,” says David Backstein, MD, MEd, FRCSC, Head of Orthopaedic Surgery at Mount Sinai Hospital in Toronto, Ontario. “In my experience, the functional outcomes for patients treated with this system have certainly been superior than the systems I’ve used in the past and patients have fewer complaints. When I see them at six or eight weeks follow-up, they’re at a different stage of recovery than I was seeing previously with traditional implant designs. I’ve been exceptionally happy with the results and feel comfortable knowing I am implanting a prosthesis with 98.8% survivorship at 17 years.”

The paper, titled, A Long Term Clinical Outcome of the Medial Pivot Knee Arthroplasty System was authored by George A Macheras et al. from the “KAT” General Hospital, Athens, Greece. In the study, 325 patients with knee osteoarthritis underwent Total Knee Arthroplasty (TKA) using the Medial-Pivot prosthesis. All patients showed a statistically significant improvement in the Knee Society clinical rating system, Western Ontario and McMaster Universities Osteoarthritis Index, and Oxford knee score. The majority of patients (94%) were able to perform age-appropriate activities with average knee flexion of 120° and 98% of patients reported relief of pain to be excellent, very good or good. Additionally, survival analysis showed a cumulative success rate of 98.8% at 17 years.

About MicroPort Orthopedics
Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/.

About MicroPort
MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com.

Forward-Looking Statements
Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Sources:

1. George A. Macheras et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee Journal, Published: January 29, 2017.

2. Thambiah, Matthew Dhanaraj et al. “Patient Satisfaction after Total Knee Arthroplasty: An Asian Perspective.” Singapore Medical Journal 56.5 (2015): 259–263. PMC. Web. 22 Feb. 2017.

Contacts

LaVoie HealthScience
Sharon Correia, 617-412-8779
scorreia@lavoiehealthscience.com

Global Hip and Knee Orthopedic Surgical Robots Industry Research Report 2016 to 2022

Posted On February 27, 2017 By OrthoSpineNews In Recon, Robotics, Top Stories /

FEBRUARY 21, 2017 – RESEARCHMOZ GLOBAL PVT. LTD.

The 2016 study has 145 pages, 64 tables and figures. Worldwide Hip and Knee Orthopedic surgical robot markets are poised to achieve significant growth. The accuracy provided by the robot is not reproducible by the human surgeon, so ultimately all surgeons will want to perform the orthopedic implants using this technology.

Robot assisted medial knee arthroplasty: orthopedic surgical robots are poised to take knee and hip surgery quality far beyond what has previously been available. The quality of knee arthroplasty is improved with robotic capability. All the advantages of surgical robots carry into the Stryker Mako orthopedic reconstruction surgical products.. When the knee and hip surgical robots are used, patients have less bleeding, reduction of post-operative pain, fewer re-admissions to hospital and faster recovery. Robots support high-precision surgery. A clinic in Switzerland, La Source, has reported a reduction in the average days of hospitalization from 10 to 6.

Knee and hip surgical robots provide consistent reproducible precision. This capability is so significant for implant surgery that the robots are positioned to become the defacto standard of care for knee and hip surgery within five years. Any one getting a knee or hip replaced will demand attention to quality of life, to maintenance of lifestyle provided by a robot when they have a joint replacement.

As next generation systems, hip and knee robotic units provide a way to improve traditional orthopedic hip and knee replacement surgery. Total hip replacement surgery has evolved dramatically as advances in technology have brought improved surgical techniques. Surgical robots are a significany [art of that advance.

Once, the penetration achieves this 35% level, all orthopedic surgeons will demand that hospitals offer robotic orthopedic surgical capability because the outcomes are more predictable and better. If the hospital does not offer the robot, the surgeon will move to a more modern facility.

Knee and Hip Surgical Robots have been impacted by the reduction in insurance payments. Payment reductions have forced hospitals to start acting as businesses. The cost of delivering care has become as much a factor as providing quality care when making decisions about patient improvement in condition. Cost-cutting has been made in the supply chain. Suppliers were examined closely for quality and cost.

READ THE REST HERE